Vigdis Nygaard
Oslo, Norway
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Assessing clinical decision support system tools in precision oncology: piloting ring testing.
Journal: ESMO real world data and digital oncology
Published: July 28, 2026
Towards an ecosystem of clinical decision support tools for precision cancer medicine.
Journal: NPJ precision oncology
Published: December 30, 2025
Desmoplastic non-infantile ganglioglioma mimicking diffuse leptomeningeal glioneuronal tumor: precision diagnostics and therapeutic implications.
Journal: Acta oncologica (Stockholm, Sweden)
Published: November 25, 2023
A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases.
Journal: Cancer research communications
Published: July 26, 2022
Novel human melanoma brain metastasis models in athymic nude fox1nu mice: Site-specific metastasis patterns reflecting their clinical origin.
Journal: Cancer medicine
Published: October 14, 2020
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study.
Journal: Acta oncologica (Stockholm, Sweden)
Published: March 27, 2020
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases.
Journal: Translational oncology
Published: December 06, 2018
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain.
Journal: Cancer immunology research
Published: October 30, 2018
Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases.
Journal: Oncotarget
Published: February 23, 2017
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate.
Journal: ESMO open
Published: January 06, 2017
Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors.
Journal: Oncotarget
Published: October 30, 2015
Metabolic reprogramming supports the invasive phenotype in malignant melanoma.
Journal: Cancer letters
Published: March 18, 2015
Last Updated: 09/26/2026